Multicentre randomized phase II study with Gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLC

被引：0
|
作者：
Ricci, S
Antonuzzo, A
Galli, L
Algeri, R
Bonifazi, V
Andrei, A
Petruzzelli, S
Dupre, C
Pegna, AL
Conte, PF
机构：
[1] Osped S Chiara, Pisa, Italy
[2] Osped Civile Misericordia, Grosseto, Italy
[3] Osped Cisanello, Pisa, Italy
[4] Osped Careggi, Florence, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
456
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [31] Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, Stage IIIB-IV nonsmall cell lung cancer
    Akerley, Wallace
    Safran, Howard
    Zaner, Ken
    Ready, Neal
    Mega, Tony
    Kennedy, Teresa
    CANCER, 2006, 107 (05) : 1050 - 1054
  • [32] Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide plus gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale
    Gebbia, V
    Galetta, D
    Caruso, M
    Verderame, F
    Pezzella, G
    Valdesi, M
    Borsellino, N
    Pandolfo, G
    Durini, E
    Rinaldi, M
    Loizzi, M
    Gebbia, N
    Valenza, R
    Tirrito, ML
    Varvara, F
    Colucci, G
    LUNG CANCER, 2003, 39 (02) : 179 - 189
  • [33] Pemetrexed plus gemcitabine versus gemcitabine plus carboplatin in patients with advanced nanoperable NSCLC: A randomized phase II study
    Hillerdal, G. N.
    Koyi, H.
    Branden, E.
    Kolbeck, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer
    Yoon, Shinkyo
    Yoo, Changhoon
    Ryu, Min-Hee
    Kang, Myoung Joo
    Ryoo, Baek-Yeol
    Park, Sook Ryun
    Yook, Jeong Hwan
    Oh, Sung Tae
    Yoo, Moon-Won
    Kim, Byung Sik
    Kang, Yoon-Koo
    GASTRIC CANCER, 2017, 20 (01) : 182 - 189
  • [35] A phase II study with cisplatin (cddp) and gemcitabine (gem) in elderly patients with advanced non-small cell lung cancer
    Buffoni, L.
    Dongiovanni, D.
    Barone, C.
    Larovere, E.
    Grillo, R.
    Gaspari, F.
    Schena, M.
    Fissore, C.
    Addeo, A.
    Ciuffreda, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 176 - 177
  • [36] CANOPY-1: Phase 3 Study of Canakinumab/Placebo plus Pembrolizumab plus Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts
    Felip, E.
    Castro, G.
    Greystoke, A.
    Solomon, B.
    Tan, D.
    Passos, V.
    Deudon, S.
    Louveau, A.
    Johnson, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S645 - S645
  • [37] COMBINATION CHEMOTHERAPY WITH VINORELBINE, IFOSFAMIDE, AND CISPLATIN - A PHASE-II STUDY IN STAGE IIIB-IV NONSMALL CELL LUNG-CANCER
    BALDINI, E
    TIBALDI, C
    CHELLA, A
    ANGELETTI, CA
    ROMANINI, A
    ANDREI, A
    ALGERI, R
    SILVANO, G
    CONTE, PF
    SEMINARS IN ONCOLOGY, 1994, 21 (03) : 12 - 15
  • [38] A multicenter phase II trial with gemcitabine (GEM) and vinorelbine (VNR) in the treatment of non-small cell lung cancer (NSCLC) stage IIIB and IV
    Laack, E
    Mende, T
    Saal, JG
    Chemaissani, A
    Scholtze, J
    Lorenz, C
    Dalhoff, K
    Hossfeld, DK
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S252 - S252
  • [39] Gemcitabin plus cisplatin versus gemcitabin plus carboplatin in patients with NSCLC, stage IIIB and IV. An interim analysis
    Zatloukal, P
    Petruzelka, L
    Zemanova, M
    Kolek, V
    Fojtu, H
    Grygarkova, I
    Sixtova, D
    Roubec, J
    Horenkova, E
    Kuta, M
    Havel, L
    Prusa, P
    Novakova, L
    Pesek, M
    LUNG CANCER: CURRENT TOPICS, 2001, : 141 - 144
  • [40] Epirubucin/gemcitabine combination in state IIIB-IV non-small cell lung cancer (NSCLC). Preliminary data of a phase I/II study
    Illiano, Alfonso
    Battiloro, Ciro
    De Marino, Valeria
    Genovese, Elvira
    Formato, Roberta
    Iaffaioli, Rosario V.
    ANNALS OF ONCOLOGY, 2004, 15 : 179 - 179
12345